2OH JM, KYUN J, CHO SW. Long-term lamivudine therapy for chronic hepatitis B in patients with and without cirrhosis [J]. Pharmacotherapy,2002,22(10) : 1226-1234.
3NEVENS F, MAIN J, HOONKOOP P, et al. Lamivudine therapy for chronic hepatitis B: A six-month randomized close-ranging study[ J ]. Gastroenterology, 1997,113(4) : 1258-1263.
4Mast EE, Alter MJ. Epidemiology of viral hepatitis: an overview.Semin Virol, 1993,4:273-283.
5Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. NEJM, 1998,339:61-68.
6Kobayashi Satsuki, Ide Tatsuya, Sata Miehio, et al. Detection of YMDD motif mutations in some lamivudine~untreated asymptomatic hepatitis B virus carriers. J Hepatol, 2001,34 : 584-586.
7Kirishima Toshihiko, Okanoue Takeshi, Daimon Yukiko, et al.Detection of YMDD mutant using a novel sensitive method in chronic liver disease type B patients before and during lamivudine treatment. J Hepatol, 2002, 37: 259-265.
9Lai CL, Chien RN, Leung NW, et al. A one-year trial of Iamivudine for chronic hepatitis B. N Engl J Med, 1998,339: 61-68.
10Barbaro G, Zechini F, Pellicel AM, et al. Long term efficacy of interferon alpha-2a and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter-randomized trial. J Hepatol, 2001,35: 40-411.
